GCP
RGLS

GSA Capital Partners’s Regulus Therapeutics RGLS Stock Holding History

GSA Capital Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,471
Closed -$45K – 1737
2021
Q3 		$45K Sell
6,471
-14,156
-69% -$104K ﹤0.01% 1349
2021
Q2 		$168K Buy
+20,627
New +$230K 0.02% 1210
2017
Q4 		– Sell
-1,698
Closed -$255K – 1777
2017
Q3 		$255K Buy
1,698
+525
+45% +$66K 0.02% 1333
2017
Q2 		$139K Buy
+1,173
New +$196K 0.01% 1559
2016
Q2 		– Sell
-120
Closed -$100K – 1877
2016
Q1 		$100K Buy
+120
New +$95.5K 0.01% 1583
2014
Q1 		– Sell
-106
Closed -$94K – 1763
2013
Q4 		$94K Buy
+106
New +$91.3K 0.01% 1570

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GSA Capital Partners's RGLS Position: Q4 2021 in Review

GSA Capital Partners sold out of Regulus Therapeutics (RGLS) in Q4 2021, closing a stake of 6,471 shares — an estimated $45K sold.

GSA Capital Partners first reported a position in RGLS in Q4 2013 and held it in 6 quarters. The position peaked at $255K in Q3 2017. 37 funds tracked by Wall St. Rank hold RGLS as of Q4 2021.

  • GSA Capital Partners reported no remaining Regulus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 6,471 Regulus Therapeutics shares in Q4 2021, an estimated $45K.
  • GSA Capital Partners first reported a position in Regulus Therapeutics in Q4 2013 and held it in 6 quarters.
  • GSA Capital Partners's Regulus Therapeutics position peaked at $255K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.